Texture indices of 4'-[methyl-11C]-thiothymidine uptake predict p16 status in patients with newly diagnosed oropharyngeal squamous cell carcinoma: Comparison with 18F-FDG uptake

Ayumi Ihara  
Kagawa University

Takashi Norikane  
Kagawa University

Katsuya Mitamura  
Kagawa University

Yuka Yamamoto  (✉️ yuka@med.kagawa-u.ac.jp)  
https://orcid.org/0000-0002-3912-4217

Kengo Fujimoto  
Kagawa University

Yasukage Takami  
Kagawa University

Emi Ibuki  
Kagawa University

Nobuyuki Kudomi  
Kagawa University

Hiroshi Hoshikawa  
Kagawa University

Jun Toyohara  
Tokyo Metropolitan Institute of Gerontology

Yoshihiro Nishiyama  
Kagawa University

Original article

Keywords: 11C-4DST, 18F-FDG, PET, oropharyngeal squamous cell carcinoma, texture

DOI: https://doi.org/10.21203/rs.3.rs-57940/v1
Abstract

**Background:** In oropharyngeal squamous cell carcinoma (OPSCC), human papillomavirus (HPV)/p16 status is important as a prognostic biomarker.

**Purpose:** We evaluated the relationship between 4¢-[methyl-$^{11}$C]thiothymidine ($^{11}$C-4DST) and $^{18}$F-FDG PET texture indices and p16 status in patients with newly diagnosed OPSCC.

**Methods:** We retrospectively reviewed the collected data of 256 consecutive, previously untreated patients with primary head and neck tumors enrolled between November 2011 and October 2019. Complete data on both $^{11}$C-4DST and $^{18}$F-FDG PET/CT studies before therapy, patients with OPSCC, and p16 status were available for 34 patients. Six of them were excluded because they did not exhibit sufficient $^{11}$C-4DST and/or $^{18}$F-FDG tumor uptake to perform textural analysis. Finally, 28 patients with newly diagnosed OPSCC were investigated. The maximum standardized uptake value (SUVmax) and 6 texture indices (homogeneity, entropy, short-run emphasis, long-run emphasis, low-gray-level-zone emphasis, and high-gray-level-zone emphasis) were derived from PET images. The presence of p16 expression in tumor specimens was examined by immunohistochemistry and compared with the PET parameters.

**Results:** Using $^{11}$C-4DST, the expression of p16 was associated with a higher homogeneity ($P = 0.012$), lower short-run emphasis ($P = 0.005$), higher long-run emphasis ($P = 0.009$), and lower high-gray-level-zone emphasis ($P = 0.042$) values. There was no significant difference between $^{18}$F-FDG PET parameters and p16 status.

**Conclusion:** Texture indices of the primary tumor on $^{11}$C-4DST PET, but not $^{18}$F-FDG PET, may be of value in predicting the condition’s p16 status in patients with newly diagnosed OPSCC.

Introduction

Identifying the imaging biomarkers of tumors is very important because this information can identify useful targets for treatment without the requirement for tissue sampling (Schillaci et al., 2017). Study in the sphere of imaging genomics (also referred to as radiogenomics) has shown the potential in getting tumor genotypes and phenotypes (Schillaci et al., 2017). Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has been built up as a biologically distinct from HPV-negative OPSCC (Ang et al., 2010). HPV-related OPSCC, usually identified by p16 as a surrogate marker, more responsive to therapy and has a better prognosis (Ang et al., 2010; Posner et al., 2011). Despite the extensive research already devoted to the biological and clinical behavior of HPV-related OPSCC, its imaging characteristics have been paid relatively little attention.

Positron emission tomography (PET) with 2-deoxy-$^{18}$F-fluoro-d-glucose ($^{18}$F-FDG) is a useful functional tool for the diagnosis and surveillance of head and neck squamous cell carcinoma (HNSCC) (Bonomo et al., 2018). While $^{18}$F-FDG directly reflects the glucose metabolism, Toyohara et al, developed 4¢-[methyl-
[11C] thiothymidine ([11C]-4DST) for cell proliferation imaging that is resistant to degradation by thymidine phosphorylase and is incorporated into DNA (Toyohara et al., 2006; Toyohara et al., 2008; Toyohara et al., 2011). [11C]-4DST PET was found by Hoshikawa et al. to provide important prognostic value in patients with HNSCC (Hoshikawa et al., 2017). The most commonly used PET semiquantitative parameter is a maximum standardized uptake value (SUVmax). Joo et al. documented an association between higher [18F]-FDG SUVmax for primary tumor and HPV-negative OPSCC (Joo et al., 2014). Another study, though, detected no significant relationship between [18F]-FDG SUV parameters for primary tumor and HPV status in patients with OPSCC or oral cavity squamous cell carcinoma (Kendi et al., 2015). Recently, increasing attention is being turned to measurements of tumor heterogeneity based on texture analysis. Chan et al. found that [18F]-FDG PET heterogeneity to be prognostically superior to traditional SUV parameters in patients with pharyngeal cancer (Chan et al., 2017). Several investigators have focused on the textural features of [18F]-FDG PET in patients with HNSCC, but the number of such studies remains very small (Chan et al., 2017; Chen et al., 2017; Cheng et al., 2015; Wang et al., 2016; Fujima et al., 2018).

As far as we could determine, no published report has focused on the relation between PET textural parameters and HPV/p16 status in patients with OPSCC. With this in mind, we evaluated the relationship between [11C]-4DST and [18F]-FDG PET texture indices and p16 status in patients with newly diagnosed OPSCC.

**Materials And Methods**

**Patients**

We conducted a retrospective analysis of prospectively collected data. The study cohort consisted of 256 consecutive, previously untreated patients with primary head and neck tumors enrolled between November 2011 and October 2019. Complete data on both [11C]-4DST and [18F]-FDG PET/CT studies before therapy, patients with OPSCC, and p16 status were available for 34 patients from July 2013 to October 2019. Six of them were excluded because they did not exhibit sufficient [11C]-4DST and/or [18F]-FDG tumor uptake to perform textural analysis. Finally, 28 patients (25 males, 3 females; mean age, 66.5 years; age range, 52-87 years) were available for the study. Their clinical data are summarized in Table 1. The study protocol was approved by our institutional ethics review committee. The requirement for informed consent was waived due to its retrospective nature.

**Radiotracer synthesis and PET/CT imaging**

[11C]-4DST and [18F]-FDG were produced using an automated synthesis system with HM-18 cyclotron (QUPID; Sumitomo Heavy Industries Ltd, Tokyo, Japan). The [11C]-4DST was synthesized using the method mentioned by Toyohara et al. (Toyohara et al., 2011).

All acquisitions were performed using a Biograph mCT 64-slice PET/CT scanner (Siemens Medical Solutions USA Inc., Knoxville, TN, USA), which has an axial field of view of 21.6 cm. The mean time
interval between $^{11}$C-4DST and $^{18}$F-FDG PET/CT scans was 6 days (range 0–24 days).

Patients were instructed to fast for at least 5 h before $^{18}$F-FDG administration. A normal glucose level in the peripheral blood was confirmed before the injection. PET emission scanning (2 min per bed position) was performed 15 min after intravenous injection of $^{11}$C-4DST (7.4 MBq/kg) and 90 min after intravenous injection of $^{18}$F-FDG (3.7 MBq/kg) from the midcranium to the proximal thighs, and co-registered with an unenhanced CT of the same region (Quality Reference mAs: 100 mAs [using CARE Dose4D]; reconstructed slice thickness: 5 mm). The PET data were reconstructed with a baseline ordered-subset expectation maximization algorithm, incorporating correction with point-spread function and time-of-flight model (2 iterations, 21 subsets). A Gaussian filter with a full-width at half-maximum of 5 mm was used as a post-smoothing filter.

Image analyses

The LIFEx software was used to extract the texture indices of PET images from the volume of interest (VOI) of the primary tumor (Nioche et al., 2018). The patients’ PET images in DICOM format were imported into this software. A board-certified nuclear medicine physician used the 40 % threshold of SUVmax to semi-automatically set the primary tumor. If non-tumoral areas of activity were incorrectly included within the VOI, adjustments were performed by the operator.

The SUVmax was calculated using the following formula: $\text{SUV} = \frac{c_{dc}}{d_i/w}$, where $c_{dc}$ is the decay-corrected tracer tissue concentration (Bq/g); $d_i$, the injected dose (Bq); and $w$, the patient’s body weight (g).

Six texture indices (homogeneity, entropy, short-run emphasis (SRE), long-run emphasis (LRE), low gray-level zone emphasis (LGZE), and high gray-level zone emphasis (HGZE) were calculated according to a report by Orlhac et al. (Orlhac et al., 2017; Orlhac et al., 2014).

Immunohistochemistry

Paraffin-embedded samples of the primary tumor obtained by surgical resection ($n = 6$) and biopsy ($n = 22$) were immunostained for p16. Staining was performed using the labeled streptavidin biotinylated antibody method with an autostaining system (Ventana Benchmark System, Ventana Medical Systems, Tucson, AZ, USA) according to the manufacturer’s protocol. Mouse monoclonal antibody against p16/INK4a (Ventana Medical Systems, Tucson, AZ, USA) was used as the primary antibody. Staining of p16 was considered positive when strong nuclear and cytoplasmic staining was present in 75 % or more of the tumor cells (Lydiatt et al., 2017).

Statistical analyses

All statistical analyses were performed using a software package (SPSS Statistics, version 26; IBM). The $^{11}$C-4DST and $^{18}$F-FDG SUVmax values were compared using the paired $t$-test. The differences between
PET parameters and p16 status were compared using the Mann-Whitney *U* test, and were considered statistically significant at *P* values less than 0.05.

**Results**

Primary tumors were detected in all patients on both $^{11}$C-4DST and $^{18}$F-FDG PET images. The mean (± SD) SUVmax for $^{11}$C-4DST (8.49± 2.25) was significantly lower than that for $^{18}$F-FDG (16.78 ± 8.19) (*P*< 0.001).

Table 2 summarizes the PET semiquantitative parameters in relation to p16 status. There was no significant difference SUVmax values between either $^{11}$C-4DST or $^{18}$F-FDG PET and p16 status. Using $^{11}$C-4DST PET, the expression of p16 was associated with a higher homogeneity (*P* = 0.012), lower SRE (*P* = 0.005), higher LRE (*P* = 0.009), and lower HGZE (*P* = 0.042) values. None of the 6 texture indices using $^{18}$F-FDG PET showed significant differences between p16-positive and p16-negative tumors. Typical PET/CT images from p16 positive and p16 negative patient are shown in Figures 1 and 2, respectively.

**Discussion**

HPV/p16 status has come to be recognized as an important risk factor and prognostic biomarker for HNSCC, especially OPSCC (Ang et al., 2010; Posner et al., 2011). We believe the present study to be the first to focus on the relation between $^{11}$C-4DST heterogeneity and the expression of p16, in patients with newly diagnosed OPSCC, as compared with $^{18}$F-FDG. Our findings suggest that four texture indices of the primary OPSCC on $^{11}$C-4DST PET may be of value in recognizing the condition's p16 status. The p16 protein plays an important role in regulation of the cell cycle. It inhibits cyclin-dependent kinases and acts as an inhibitor of the cell cycle. Therefore, it is reasonable to consider some relationship between texture indices of $^{11}$C-4DST PET and p16 status was detected. However, the biological meanings of this findings are not clear.

Several researches have investigated the association between $^{18}$F-FDG PET findings and tumor HPV/p16 status in patients with HNSCC (Joo et al., 2014; Kendi et al., 2015; Chen et al., 2017; Tahari et al., 2014; Surov et al., 2019; Schouten et al., 2016; Huang et al., 2015). Some noted $^{18}$F-FDG PET SUV parameters to be significantly higher in HPV-negative as compared with HPV-positive primary OPSCC (Joo et al., 2014; Tahari et al., 2014; Surov et al., 2019; Schouten et al., 2016). However, such results have not always been consistent concerning the correlation between $^{18}$F-FDG PET parameters and HPV/p16 status (Kendi et al., 2015; Chen et al., 2017; Huang et al., 2015). Chen et al. demonstrated that the expression of p16 was not related to the textural features on $^{18}$F-FDG PET in patients with pharyngeal cancer (Chen et al., 2017). Huang and colleagues did not observe a significant relationship either between $^{18}$F-FDG SUV parameters including volumetric factors and p16 status in patients with OPSCC (Huang et al., 2015). In the present study, we similarly did not identify significant correlations between SUVmax values and textural parameters on $^{18}$F-FDG PET and expression of p16 status. This discrepancy in the significance
of semiquantitative $^{18}$F-FDG PET parameters may be attributable to differences in patient populations and in imaging protocols as well as image analyses or as yet other unidentified factors in the respective studies.

To date, there are no reports comparing $^{11}$C-4DST parameters and HPV/p16 status in patients with OPSCC. In the present study, the expression of p16 associated with higher homogeneity, lower SRE, higher LRE, and lower HGZE values on $^{11}$C-4DST PET, although this association was not present on $^{11}$C-4DST SUVmax. The prognostic information of $^{18}$F-FDG PET textural indices in patients with pharyngeal cancer has been studied (Chan et al., 2017; Chen et al., 2017; Cheng et al., 2015; Wang et al., 2016; Fujima et al., 2018; Cheng et al., 2013). Chan et al. proved that heterogeneity on $^{18}$F-FDG PET was prognostically superior to traditional SUV parameters in such patients (Chan et al., 2017). According to Fujima et al., higher $^{18}$F-FDG homogeneity was an independent predictor of prognosis in patients with pharyngeal cancer, although this association was not present in the case of $^{18}$F-FDG SUV parameters (Fujima et al., 2018). Chen et al. also demonstrated that $^{18}$F-FDG heterogeneity indices were more informative than classical SUV indices in the prediction of patient prognosis in pharyngeal cancer (Chen et al., 2017). Taken together, the textural indices compared to classical SUV parameters might have a role in determining the prognosis in patients with pharyngeal cancer. Such findings are attributable to the inability of classical PET parameters such as SUV to delineate tumor heterogeneity, which has been explained by a number of underlying factors such as cellular proliferation, cellularity, angiogenesis, necrosis, and vascularization (Huang et al., 2015). However, the exact biologic correlates of these PET heterogeneity parameters remain to be determined. Further studies will be needed to investigate the relation between PET textural parameters and tumor biology in patients with a variety of tumor types.

Limitations of the present study include its small sample size and retrospective design. The histopathological samples represent only a small portion of the tumors, whereas PET was analyzed as a whole tumor measurement. Only p16 was used as a surrogate marker for HPV infections because HPV DNA testing was not available. Additional large prospective studies will be needed to verify and expand the present results.

Chan et al. found the combination of $^{18}$F-FDG PET heterogeneity parameters and dynamic contrast-enhanced MRI parameters to be beneficial in the prediction of patient prognosis in pharyngeal cancer (Chan et al., 2017). Advances in hardware such as simultaneous PET/MRI will help to further facilitate imaging research on analysis of tumor heterogeneity. Few tumor heterogeneity studies have yet been undertaken using newer radiopharmaceuticals other than $^{18}$F-FDG. Further studies will be needed to evaluate texture parameters using different imaging tools and different radiopharmaceuticals to clarify their potential clinical information.

Conclusion
The results of this preliminary study, albeit conducted in a small patient population, documented associations between the expression of p16 with a higher homogeneity, lower SRE, higher LRE, and lower HGZE values on $^{11}$C-4DST PET in patients with newly diagnosed OPSCC, while this association was not present on $^{18}$F-FDG PET.

**Abbreviations**

OPSCC: Oropharyngeal squamous cell carcinoma; HPV: Human papillomavirus; PET: Positron emission tomography; $^{18}$F-FDG: 2-deoxy-2-$^{18}$F-fluoro-D-glucose; HNSCC: Head and neck squamous cell carcinoma; $^{11}$C-4DST: 4¢-[methyl-$^{11}$C] thiothymidine; SUVmax: Maximum standardized uptake value; VOI: Volume of interest; SRE: Short-run emphasis; LRE: Long-run emphasis; LGZE: Low gray-level zone emphasis; HGZE: hHgh gray-level zone emphasis

**Declarations**

**Authors’ contribution**

Conception and design of the study: AIN, YY, YN. Patient recruitment: AIN, HH. Data analysis and interpretation: AIN, TN, KM, KF, YT El, NK. Manuscript preparation: AIN, YY, JT, YN. All authors contributed to discussion of results and have read and approved the final manuscript.

**Funding**

No funding was received.

**Availability of data and material**

All datasets used during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the institutional ethical review committee (approval number 2019176). The requirement for informed consent was waived due to its retrospective nature.

**Consent for publication**

Not applicable. All images and data were anonymous.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**
1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–

2. Bonomo P, Merlotti A, OlmettoE, Bianchi A, Desideri I, Bacigalupo A, et al. What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45:2122–

3. Chan SC, Cheng NM, Hsieh CH, Ng SH, Lin CY, Yen TC, et al. Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. 2017;8: 62606–21.

4. Chen SW, Shen WC, Lin YC, Chen RY, Hsieh TC, Yen KY, et al. Correlation of pretreatment 18F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes. Eur J Nucl Med Mol Imaging, 2017;44:567–80.

5. Cheng NM, Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, et al. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J Nucl Med. 2013;54:1703–9.

6. Cheng NM, Fang YH, Lee LY, Chang JT, Tsan DL, Ng SH, et al. Zone-size non-uniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2015;42:419–

7. Fujima N, Hirata K, Shiga T, Li R, Yasuda K, Onimaru R, et al. Integrating quantitative morphological and intratumoural textural characteristics in FDG-PET for the prediction of prognosis in pharynx squamous cell carcinoma patients. Clin Radiol. 2018;73:1059.e1-8.

8. Hoshikawa H, Mori T, Maeda Y, Takahashi S, Ouchi Y, Yamamoto Y, et al: Influence of volumetric 4'-[methyl-11C]-thiothymidine PET/CT parameters for prediction of the clinical outcome of head and neck cancer patients. Ann Nucl Med 2017;31:63–

9. Huang YT, Kumar AR, Bhuta S. 18F-FDG PET/CT as a semiquantitative imaging marker in HPV-p16-positive oropharyngeal squamous cell cancers. Nucl Med Commun. 2015;36:16-20.
10. Joo YH, Yoo IeR, Cho KJ, Park JO, Nam IC, Kim MS. Preoperative $^{18}$F-FDG PET/CT and high-risk HPV in patients with oropharyngeal squamous cell carcinoma. Head Neck. 2014;36:323–

11. Kendi ATK, Magliocca K, Corey A, Nickleach DC, Galt J, Higgins K, et al. Do $^{18}$F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? Clin Nucl Med. 2015;40:e196–200.

12. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:122–

13. Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Research. 2018;78:4786–9.

14. Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in $^{18}$F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014; 55:414–22.

15. Orlhac F, Nioche C, Soussan M, Buvat Understanding Changes in Tumor Texture Indices in PET: A Comparison Between Visual Assessment and Index Values in Simulated and Patient Data. J Nucl Med. 2017; 58:387–92.

16. Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol 2011; 22:1071–

17. Schillaci O, Urbano Personalized medicine: A new option for nuclear medicine and molecular imaging in the third millennium. Eur J Nucl Med Mol Imaging. 2017;44:563–6.

18. Schouten CS, Hakim S, Boellaard R, Bloemena E, Doornaert PA, Witte Bl, et al. Interaction of quantitative $^{18}$F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. Head Neck. 2016;38:529–35.

19. Surov A, Meyer HJ, Höhn AK, Winter K, Sabri O, Purz S. Associations between $[^{18}\text{F}]$ FDG-PET and complex histopathological parameters including tumor cell count and expression of Ki 67, EGFR, VEGF, HIF-1$\alpha$, and p53 in head and neck squamous cell carcinoma. Mol Imaging Biol. 2019;21:368–

20. Tahari AK, Alluri KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. Clin Nucl Med. 2014;39:225–31.

21. Toyohara J, Kumata K, Fukushi K, Irie T, Suzuki K. Evaluation of 4′-[methyl-$^{14}$C]thiothymidine for in vivo DNA synthesis imaging. J Nucl Med. 2006;47:1717–

22. Toyohara J, Okada M, Toramatsu C, Suzuki K, Irie T. Feasibility studies of 4′-[methyl-$^{11}$C]thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol. 2008;35:67–

23. Toyohara J, Nariai T, Sakata M, Oda K, Ishii K, Kawabe T, et al. Whole-body distribution and brain tumor imaging with $^{11}$C-4DST: a pilot study. J Nucl Med. 2011;52:1322–Hoshikawa H, Yamamoto Y,
Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020–6. Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020–6. Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020–6.

24. Wang HM, Cheng NM, Lee LY, Fang YH, Chang JT, Tsan DL, et al. Heterogeneity of $^{18}$F-FDG PET combined with expression of EGFR may improve the prognostic stratification of advanced oropharyngeal carcinoma. Int J Cancer. 2016;138:731–

**Tables**

Due to technical limitations, Tables 1-2 are provided in the Supplementary Files section.

**Figures**
PET/CT images from a 67-year old male diagnosed with p16-positive oropharyngeal squamous cell carcinoma in the left palatine tonsil. Transverse 11C-4DST PET image (a) and fused PET/CT image (b) show an increased uptake in the primary tumor (SUVmax = 7.41, homogeneity = 0.344, entropy = 2.130, SRE = 0.948, LRE = 1.220, LGZE = 0.00676, and HGZE = 199.90). Transverse 18F-FDG PET image (c) and fused PET/CT image (d) also show an increased uptake in the primary tumor (SUVmax = 14.42, homogeneity = 0.206, entropy = 2.230, SRE = 0.979, LRE = 1.080, LGZE = 0.00180, and HGZE = 867.60).
PET/CT images from a 66-year old male diagnosed with p16-negative oropharyngeal squamous cell carcinoma in the soft palate. Transverse 11C-4DST PET image (a) and fused PET/CT image (b) show an increased uptake in the primary tumor (SUVmax = 8.00, homogeneity = 0.295, entropy = 2.050, SRE = 0.965, LRE = 1.140, LGZE = 0.00514, and HGZE = 260.00). Transverse 18F-FDG PET image (c) and fused PET/CT image (d) also show an increased uptake in the primary tumor (SUVmax = 14.57, homogeneity = 0.194, entropy = 1.970, SRE = 0.986, LRE = 1.060, LGZE = 0.00168, and HGZE = 843.90).

Figure 2
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Table2.docx
- Table1.docx